Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from BofA

Beyond snubbing Tinder, Bumble, and casual flings, more than half of Gen Z is spending $0 monthly on dating, BofA finds

Gen Z’s economic anxiety—as well as disinterest in casual dating—has led many young people to spend little to nothing on dates.

Fortune

The last time the Fed cut rates against rising inflation was right before the Great Financial Crisis. BofA warns of the 'Ghosts of 2007'

Conditions are like they were in 2007, or in the late 1990s, depending on how you look at the Fed raising rates during rising inflation, and the top 50 stocks dominating.

Fortune

Carlsmed's Personalized Spine Implants Get Significant Reimbursement Advantage

Carlsmed Inc. (NASDAQ:CARL), an AI-powered innovator in spine surgery, is poised for significant growth following key advancements and strong analyst projections.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

GoodRx Is Soaring on a Novo Nordisk Deal. Should You Buy GDRX Stock Here?

GoodRx stock soars after announcing GLP-1 partnership with Novo Nordisk. A Bank of America analyst recommends selling GDRX shares into the strength before they crash again.

Barchart

Novo Nordisk's Lead Fades, Eli Lilly Holds Course For Outsized Gains, Says Analyst

On Thursday, Eli Lilly and Co. (NYSE:LLY) said it will sharply increase the list price of its weight-loss and type 2 diabetes drug Mounjaro (tirzepatide) in the United Kingdom.

Benzinga

More outages, aging infrastructure, and bicoastal dysfunction: BofA warns America’s grid is 30% to 46% ‘beyond its useful life’

Bank of America Institute warns: “Grid reliability is worse today than in the early 2000s.”

Fortune

What's Going On With Coherent Stock On Thursday?

Coherent Corp. (NYSE:COHR) shares plummeted on Thursday after the company announced it will sell its aerospace and defense unit to Advent for $400 million.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Should You Buy the Post-Earnings Dip in Pinterest Stock?

Pinterest stock slips despite reporting better-than-expected revenue and user growth in Q2. BofA analyst says PINS shares could climb significantly to $44.

Barchart

Bank of America sees stagflation, not recession—and no rate cut this year. It’s because of 2 specific Trump policies

It all comes down to the labor market, immigration, and tariffs. What is really going on in terms of how many workers are available?

Fortune

As Super Micro Computer Stock Absolutely Plunges, Should You Buy the SMCI Dip?

Super Micro stock tanks on disappointing Q4 earnings and weaker-than-expected guidance. Here’s why SMCI shares aren’t worth buying on the post-earnings decline.

Barchart

Here’s what the doomsayers are getting wrong about the job market, according to a Wall Street veteran

“This implies that the weak gains in payrolls in recent months might have something to do with the supply of labor.”

Fortune

Ford's Q2 Shines, But Analysts Warn Of Recall Hangover And Cost Pressures

Ford Motor Company (NYSE:F) shares are trading higher on Thursday after the automaker posted second-quarter results that exceeded Wall Street expectations on Wednesday, driven by solid vehicle volumes and favorable pricing trends.

Benzinga

Cautious Optimism As Merck Leans On Oncology Amid Gardasil Vaccine Concerns

Pharmaceutical giants are navigating a complex landscape of fluctuating demand and regulatory hurdles, impacting their financial performance and strategic outlook. Merck Co. Inc. (NYSE:MRK) is the latest to face these challenges, as its recent earnings report reveals a mixed bag of successes and setbacks.

Benzinga

‘Not just a cyclical recovery, but a boom.’ BofA says a ‘key tail risk’ is that the Trump economy will actually start to take off

“Today a confluence of factors argue that the key tail risk that may not be priced in is not just a cyclical recovery, but a boom,” BofA Research analysts write.

Fortune

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Elevidys Halt Sparks Analyst Downgrades—Sarepta Races To Revise Label

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced Monday it will voluntarily and temporarily pause all U.S. shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy, effective July 22.

Barchart

Is Bank of America Stock a Buy, Sell, or Hold After Q2 Earnings?

Is BofA’s Q2 revenue miss just a brief pause? Or a warning sign to rethink your position?

Fortune

Quantum computing is so fire — No, seriously. BofA says it could be humanity's biggest breakthrough since the discovery of fire

"A technology that can perform endless complex calculations in zero-time, warp-speeding human knowledge and development."

Benzinga

Why Morgan Stanley Offers A Compelling Long-Term Investor Story

Morgan Stanley (NYSE:MS) on Wednesday reported a second-quarter 2025 earnings of $2.13, up from $1.82 a year ago and beating the consensus of $2.02.

Get all your
news in one place.

100's of premium titles.
One news app.

Evening Standard

London stocks slip after reports that Trump will fire Federal Reserve boss

The FTSE 100 index closed down 11.77 points, 0.1%, at 8,926.55.

Fortune

Americans spend $40 billion on their pets’ health care. Chewy has a plan to get more of their money

Americans adopted roughly 23 million pets during the pandemic, and Bank of America Research sees the "COVID cohort" nearing middle age.

Benzinga

S&P 500 Defies Odds With Rare Rally — But 'Toppy' Sentiment Creeps In

The U.S. stock market has just completed one of its strongest three-month runs in history, with the SP 500 soaring 26% between April 9 and July 10, a pace of gains rarely seen. While historical analogues suggest further upside, signs of overheated investor sentiment are starting to worry market watchers.

Benzinga

Honeywell Set To Soar? Analyst Says Smart Price Hikes, Solid Backlog, M&A Could Drive Big Gains

BofAmerica Securities analyst Andrew Obin maintained a Buy on Honeywell International (NASDAQ:HON) and increased the price target from $250 to $275 on Monday.

Benzinga

Is Bristol-Myers Squibb Still An Undervalued Biopharma Play?

Bristol-Myers Squibb Co. (NYSE:BMY) is gearing up to announce its second-quarter 2025 earnings on July 31, with expectations for adjusted earnings of $1.585 per share on sales of $11.31 billion, according to data from Benzinga Pro.

Benzinga

Southwest Airlines Adds St. Thomas To Growing Caribbean Network

Southwest Airlines Co. (NYSE:LUV) plans to expand its route network in 2026, starting with new service to Cyril E. King International Airport (STT) in St. Thomas, U.S. Virgin Islands.

Benzinga

Bank Of America Loves These 8 Stocks For Third Quarter—And Says To Dump These 2 Fast

Bank of America dropped its top 10 stock ideas for the third quarter of 2025, and the list includes some familiar names like Boeing Co. (NYSE:BA) and Cisco Systems Inc. (NASDAQ:CSCO)—but also a couple of bearish calls investors might not see coming.

1 … 4 5 6 7

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Office for National Statistics

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.